Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence Reply - Aix-Marseille Université Access content directly
Journal Articles LANCET DIABETES & ENDOCRINOLOGY Year : 2022

Dates and versions

hal-03780355 , version 1 (18-04-2023)

Identifiers

  • HAL Id : hal-03780355 , version 1

Cite

Maria Fleseriu, Frederic Castinetti, Monica Gadelha, Andrea Giustina, Andre Lacroix, et al.. Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence Reply. LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (6), pp.385-387. ⟨hal-03780355⟩
28 View
21 Download

Share

Gmail Mastodon Facebook X LinkedIn More